Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
M&A Deal

Lineage Cell Therapeutics Acquires NeuroAirmid in $2.4 Million Deal for Huntington's Program

Lineage Cell Therapeutics has completed the acquisition of NeuroAirmid Therapeutics, securing the HUNT1 clinical-stage neural cell therapy program for Huntington’s Disease. The transaction expands Lineage’s pipeline to three clinical-stage assets while integrating the program into its proprietary manufacturing platform.

Woman, massage, therapy, physiotherapy. Stock photo illustrating Lineage Cell Therapeutics' M&A deal story.
Lineage Cell Therapeutics, Inc. · Healthcare · Photo: whitesession / Pixabay
Key numbers
Deal value$2M
Share of market cap1.0%
Share of annual revenue16.5%

Key highlights

  • Acquisition of NeuroAirmid Therapeutics for $2.4 million upfront cash payment
  • Addition of HUNT1 (hNSC-01), a Phase 1b/2a stage candidate for Huntington’s Disease
  • Assumption of a $3.1 million co-funding obligation for the ongoing REGEN4HD study
  • Integration of the HUNT1 program into the proprietary AlloSCOPE 5D manufacturing platform
  • Access to external funding through a $12 million CIRM award supporting clinical development

What Is the Deal?

Lineage Cell Therapeutics acquired all outstanding shares of NeuroAirmid Therapeutics in a deal closed concurrently with the signing of the purchase agreement on November 12, 2026. The acquisition brings the HUNT1 (hNSC-01) program into Lineage's portfolio, a pluripotent stem cell-derived therapy currently in a Phase 1b/2a clinical trial for Huntington’s Disease. Under the terms, NeuroAirmid became a wholly owned subsidiary of Lineage. The deal also includes an exclusive license agreement with The Regents of the University of California for the underlying neural cell therapy technology used in the program.

Deal Structure & Terms

  • Immediate cash payment of $2.4 million to NeuroAirmid stockholders at closing
  • Assumption of a $3.1 million co-funding obligation toward the ongoing REGEN4HD study
  • Acquisition includes rights to a $12 million CIRM grant issued in April 2026
  • Lineage takes responsibility for future manufacturing and optimization activities
  • The co-funding obligation is expected to be paid through February 2030

Strategic Rationale

“Today, we closed the acquisition of NeuroAirmid Therapeutics adding HUNT1, a third clinical-stage asset to our development pipeline. HUNT1 is a pluripotent stem cell derived, clinical-stage neural cell therapy program, with the potential to validate a new cell-based treatment modality for Huntington’s Disease.”

Brian M. Culley, CEO, Lineage Cell Therapeutics

Financial Context

Lineage enters this acquisition with a market capitalization of approximately $250.5 million and a cash position of $32.4 million as of September 30, 2026. The company reported quarterly revenue of $1.1 million against a net loss of $4.8 million for the third quarter. Management indicates that current liquid assets are sufficient to support operations into the second quarter of 2028. The deal value of $2.4 million represents a disciplined capital allocation of less than 1% of the company's market value, aimed at diversifying the allogeneic cell transplant portfolio beyond its flagship OpRegen program.

Lineage Cell Therapeutics, Inc. share price · last month
Line chart of Lineage Cell Therapeutics, Inc.'s share price over the last month, from $0.95 on 19 Oct → $0.80 on 16 Nov; our story on 12 Nov at $0.99.

Down 19.7% since our story on 12 Nov: $0.99 when we broke it → $0.80 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$0.95
20 Oct$0.97
21 Oct$0.95
22 Oct$0.99
23 Oct$1.00
26 Oct$1.00
27 Oct$1.03
28 Oct$1.04
29 Oct$1.03
30 Oct$1.00
2 Nov$1.01
3 Nov$1.01
4 Nov$1.03
5 Nov$0.98
6 Nov$1.02
9 Nov$1.08
10 Nov$1.04
11 Nov$1.11
12 Nov$0.99
13 Nov$0.91
16 Nov$0.80

Industry Landscape

The biotechnology sector is seeing increased consolidation around advanced cell therapies as companies seek to industrialize manufacturing processes. Huntington’s Disease remains a significant unmet medical need, characterized by the progressive degeneration of nerve cells in the brain. Lineage’s integration of HUNT1 into its AlloSCOPE 5D manufacturing platform reflects a broader industry trend of applying proprietary production technologies to specialized clinical assets. By leveraging a common cell line across multiple programs, firms aim to reduce the time and cost associated with scaling pluripotent cell-derived therapies for late-stage registrational trials.

Management commentary

“This transaction reflects the disciplined approach to capital allocation and strategic fit that we believe our investors have come to expect from Lineage. HUNT1 was created on the same proprietary cell line that Lineage uses and is compatible with its AlloSCOPE “5D” technology, providing us with a head start on our planned contributions.”

Brian M. Culley, Lineage CEO
Lineage Cell Therapeutics, Inc. · financial snapshot
Share price$0.99
Market cap$250M
Revenue (annual)$15M
1-month price change+8.82%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Lineage Cell Therapeutics, Inc. announcing the acquisition of NeuroAirmid Therapeutics, Inc.

Read the filing ↗

Track Lineage Cell Therapeutics, Inc. live

Get the next Lineage Cell Therapeutics, Inc. SEC filing seconds after it lands.

More in M&A & Deals

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.